Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
the other only received the liquid adjuvant; the other only received the liquid adjuvant; This non-serious case was reported by a nurse via patient support programs and described the occurrence of inappropriate preparation of medication in a adult patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On 28-MAR-2025, the patient received the 1st dose of Arexvy. On 28-MAR-2025, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: the other only received the liquid adjuvant) and inappropriate dose of vaccine administered (Verbatim: the other only received the liquid adjuvant). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 28-MAR-2025 The two older adult patients was vaccinated with first dose of Arexvy vaccine, one with mixed components and the other only received the liquid adjuvant. The clinic was unsure which patient received the full dose and which patient received partial dose. The patients were a married couple. The Medical Assistant in the clinic administered a correct dose of Arexvy for one patient and the other only received the adjuvant liquid, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.